Endo International

Endo International Plc operates as a pharmaceutical company, which engages in the development, manufacture, and distribution of branded and generic pharmaceutical products. It operates through the following segments: Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals and International Pharmaceuticals. The Branded Pharmaceuticals segment conducts certain operations in the U.S. through leased and owned manufacturing properties in Pennsylvania, New York and New Jersey, as well as certain administrative and R&D functions through leased properties in Pennsylvania. The Sterile Injectables segment includes manufacturing, quality assurance, research and development, and administration functions. The Generic Pharmaceuticals segment is composed of manufacturing, distribution, quality assurance and administration functions, as well as certain research and development functions. The International Pharmaceuticals segment’s operations are currently conducted through Paladin’s leased headquarters in Montreal, Canada. The company was founded in 1997 and is headquartered Dublin, Ireland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The company’s Endo Pharmaceuticals segment offers branded prescription products,.

Endo International plc (ENDP) CEO Blaise Coleman on Q3 2021 Results - Earnings Call Transcript

Endo (ENDP) tops third-quarter earnings and sales estimates and raises its forecast. Shares are up in pre-market trading.

Endo (ENDP) Beats Q3 Earnings & Sales Estimates, Raises View

Endo (ENDP) delivered earnings and revenue surprises of 73.91% and 15.60%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Endo International (ENDP) Q3 Earnings and Revenues Surpass Estimates

DUBLIN, Nov. 4, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) today reported financial results for the third-quarter ended September 30, 2021. "We delivered strong third-quarter results driven by outstanding execution across all of our businesses.

Endo Reports Third-Quarter 2021 Financial Results And Raises 2021 Financial Guidance

Moderna

Novavax

Regeneron Pharmaceuticals

Zoetis

Let us take a look at five drug/biotech companies due to release their quarterly results on Nov 4.

Drug, Biotech Stock Q3 Earnings on Nov 4: MRNA, REGN & More

Hive Blockchain Technologies Ltd

Electrameccanica

Check these three penny stocks out for your November watchlist The post Best Penny Stocks to Buy Today? 3 to Watch in Early November appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Today? 3 to Watch in Early November

California State Court hands Endo and other opioid producers a temporary win in liability trial. Tentative ruling directs manufacturers to file a statement of decision within 30 days.

Endo: A Win In California But Equity Value Still A Question

DUBLIN, Nov. 2, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that, following a months-long trial, one of the first public nuisance cases filed against manufacturers of prescription opioid medications has ended with a California state court tentatively ruling that the defendants, including Endo's wholly-owned subsidiaries Endo Health Solutions Inc. and Endo Pharmaceuticals Inc., are not liable. The tentative ruling, issued on November 1, directs Endo and the other defendants to prepare and file a proposed statement of decision and a proposed judgment consistent with the tentative ruling within 30 days.

California State Court Issues Tentative Ruling in Endo's Favor Following Opioid Trial

AbbVie

Johnson & Johnson

Teva Pharmaceutical

A California judge cleared four drugmakers of liability after a monthslong trial accusing the companies, including Johnson & Johnson JNJ, +0.09% and Endo International PLC ENDP, +8.94% , of causing widespread opioid addiction in the state.

The Wall Street Journal: Opioid makers cleared of liability in California lawsuit

A California judge on Monday said he would rule against several large counties who accused four drugmakers of fueling an opioid epidemic, saying they had failed at trial to prove their $50 billion case.

California judge rules for drugmakers in major opioid lawsuit

Endo (ENDP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Endo International (ENDP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

DUBLIN, Oct. 25, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today the launch of their first-ever XIAFLEX® (collagenase clostridium histolyticum) television commercial, Bent Carrot. The spot introduces men to XIAFLEX as the first and only nonsurgical FDA-approved treatment for Peyronie's disease (PD) and encourages them to seek treatment if they believe they may have the condition, in which a buildup of fibrous scar tissue (plaque) causes a curvature of the penis.

Endo Announces First-Ever XIAFLEX® (collagenase clostridium histolyticum) Television Commercial, Bent Carrot, and Branded Campaign to Raise Awareness of Peyronie's Disease

DUBLIN, Oct. 22, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that new post-hoc data from two Phase 3 studies of XIAFLEX® (collagenase clostridium histolyticum, or CCH) in treating men with Peyronie's disease (PD) will be presented today in an oral presentation during the Sexual Medicine Society of North America (SMSNA) annual meeting. "The data analysis discusses the importance of patient adherence when treating PD with XIAFLEX," said Dr. Matthew J.

Endo Presents New XIAFLEX® (collagenase clostridium histolyticum) Data Analysis at Sexual Medicine Society of North America (SMSNA) Annual Meeting

Endo (ENDP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for Endo (ENDP)

Kosmos Energy

OncoSec Medical

Sesen Bio Inc.

Waitr Holdings Inc

5 Penny Stocks To Buy According To Analysts The post 5 Top Penny Stocks Analysts Say To Buy With 119%-430% Price Targets appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Top Penny Stocks Analysts Say To Buy With 119%-430% Price Targets

DUBLIN, Oct. 5, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) will announce its third–quarter 2021 financial results on November 4, 2021 and members of its senior management team will host a conference call and webcast on November 5, 2021 at 7:30am ET before the U.S. financial markets open. The dial-in number to access the call is U.S./Canada (866) 497-0462, International (678) 509-7598, and the passcode is 6052178.

Endo to Announce Third Quarter 2021 Financial Results

DUBLIN, Sept. 30, 2021 /PRNewswire/ --  Survey data indicated a high level of consensus among expert hand surgeons for using CCH for the treatment of metacarpophalangeal (MP) and/or joint contractures of varying severity and MP and/or interphalangeal thumb contractures; data also achieved consensus for using CCH for treating proximal interphalangeal (PIP) joint contractures of varying severities Consensus-based findings among expert hand surgeons point to wide-ranging application of CCH for the treatment of DD for patients with varying degrees of disease severity and functional impairment Endo International plc (NASDAQ: ENDP) today announced results from the first two rounds of Delphi research exploring the expert positions of hand surgeons on the appropriate treatment of Dupuytren's disease (DD) with collagenase clostridium histolyticum (CCH) in patients with varying degrees of disease severity and functional impairment.

Endo Presents New Investigational Collagenase Clostridium Histolyticum (CCH) Survey Data at American Society for Surgery of the Hand (ASSH) Annual Meeting

ElectroCore Inc

AB Corporate Bond ETF

Powerbridge Technologies Co Ltd

Solid Biosciences

Uxin Ltd - ADR

WiMi Hologram Cloud

Penny stocks have a place in every portfolio when adjusted for risk. These 7 have the added safety of a Nasdaq listing.

7 Best Penny Stocks to Buy on the Nasdaq for October

DUBLIN, Sept. 28, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) ("Endo") today announced that it has reached an agreement in principle with the Louisiana Attorney General's office to settle all opioid-related cases and claims of the state and other Louisiana governmental persons and entities in exchange for a total payment of $7.5 million.

Endo Reaches Agreement in Principle to Settle Louisiana Governmental Opioid Cases and Claims

Castor Maritime Inc

Predictive Oncology Inc

Why investors are watching these penny stocks right now The post Do These Penny Stocks Deserve a Place On Your Watchlist? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Do These Penny Stocks Deserve a Place On Your Watchlist?

DUBLIN, Sept. 22, 2021 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that one of its operating companies, Par Pharmaceutical, Inc. (Par), has begun shipping the generic version of Pfizer's Chantix® (varenicline), 0.5 mg and 1 mg tablets, following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application.

Endo Launches First and Only Generic Version of Chantix® (varenicline) Tablets in the United States

Endo (ENDP) stock gains following the settlement of three opioid cases in the New York State in exchange for a total payment of $50 million.

Endo (ENDP) Gains on Settlement of Opioid Cases in New York for $50M

Endo International (NASDAQ: ENDP) shares are trading higher going into the close after the company announced it settled New York state opioid cases and provided an update on remaining opioid litigation. The company late Thrusday announced it has settled three consolidated cases pending in Suffolk County Supreme Court in the State of New York related to the marketing and sale of prescription opioid medications for a total payment of $50 million.

Why Shares Of Endo International Surged On Friday

Camber Energy

China Online Education Group

Elite Education Group International Ltd

Looking for big gaining penny stocks to watch? Here's 4 that gapped up today The post Biggest Gaining Penny Stocks to Buy?

Biggest Gaining Penny Stocks to Buy? 4 to Watch Right Now

Endo International plc (NASDAQ: ENDP) climbed more than 50% this morning after it said late on Thursday it will pay $50 million to settle opioid claims by the New York state and its Suffolk and Nassau counties. “I'm happy our clients can get closure, and it has kept Endo out of bankruptcy, that would have […] The post Endo International stock shoots up 50% as it settles opioid claims appeared first on Invezz.

News for Endo International Stock (ENDP)